CS
IMUC

Credit Suisse’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Credit Suisse’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-931
Closed -$42K – 4904
2014
Q2 		$42K Buy
931
+235
+34% +$11.3K ﹤0.01% 4601
2014
Q1 		$34K Sell
696
-2,775
-80% -$136K ﹤0.01% 4601
2013
Q4 		$128K Buy
+3,471
New +$329K ﹤0.01% 4434
2013
Q3 		– Sell
-5,429
Closed -$422K – 4559
2013
Q2 		$422K Buy
+5,429
New +$520K ﹤0.01% 3416

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Credit Suisse's IMUC Position: Q3 2014 in Review

Credit Suisse sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2014, closing a stake of 931 shares — an estimated $42K sold.

Credit Suisse first reported a position in IMUC in Q2 2013 and held it in 4 quarters. The position peaked at $422K in Q2 2013. 39 funds tracked by Wall St. Rank hold IMUC as of Q3 2014.

  • Credit Suisse reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2014 after selling out during the quarter.
  • Credit Suisse sold 931 ImmunoCellular Therapeutics, Ltd. shares in Q3 2014, an estimated $42K.
  • Credit Suisse first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 4 quarters.
  • Credit Suisse's ImmunoCellular Therapeutics, Ltd. position peaked at $422K in Q2 2013.
  • 39 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2014.

Based on Credit Suisse's 13F filing for Q3 2014, filed 14 Nov 2014.